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Abstract
Current technology to isolate viable cytokine-producing antigen-specific primary human T cells is
limited to bi-specific antibody capture systems, which suffer from limited sensitivity and high
background. Here, we describe a novel procedure for isolating antigen-specific human T cells
based on their ability to produce tumor necrosis factor (TNF)-α. Unlike many cytokines, TNF-α is
initially produced in a biologically active membrane-bound form that is subsequently cleaved by
TNF-α converting enzyme (TACE) to release the soluble form of TNF-α. By preventing this
cleavage event, we show that TNF-α can be ‘trapped’ on the surface of the T cells from which it
originates and directly labeled for viable isolation of these antigen-specific T cells. Together with
other existing sorting procedures to isolate activated T cells, this new technique should permit the
direct isolation of multi-functional T lymphocytes for further protein and gene expression
analyses, as well as a detailed functional assessment of the potential role that TNF-α producing T
cells play in the adaptive immune system.
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1. Introduction
CD8+ T cells are essential for the effective control and clearance of intracellular pathogens,
and play a central role in tumor surveillance. In response to antigenic stimuli, CD8+ T cells
can deploy an extensive array of effector functions, including perforin-mediated
cytotoxicity, the induction of apoptosis via Fas and TNF-α (TNF from hereon), and the
production of numerous immunomodulatory cytokines and chemokines (Harty et al., 2000).
Procedures to identify and isolate CD8+ T cells with these particular properties remain
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critically important for our understanding of CD8+ T cell function and the development of
CD8+ T cell-based immunotherapeutic strategies.
Although basic analysis of CD8+ T cell function and phenotype is relatively straightforward
through the use of flow cytometry, there are few procedures that permit the isolation of
viable antigen-specific CD8+ T cells for further study. Staining with fluorescent MHC class
I tetramers, or multimers with higher order valencies, remains the gold standard for the
precise identification and isolation of antigen-specific CD8+ T cells (Altman et al., 1996;
Wooldridge et al., 2009). However, this approach is limited to defined specificities, requires
unique and costly reagents, and provides no assessment of functional capacity. Furthermore,
it is clear that not all tetramer+CD8+ T cells are functional, at least as assessed by current
techniques, and that not all functional cells can be identified with MHC class I tetramers due
to threshold differences that distinguish activation from physical staining (Goepfert et al.,
2000; Chattopadhyay et al., 2008). Currently, there are few available methods for the
isolation of viable antigen-specific CD8+ T cells based on functional responses. As we have
shown previously, exposure of CD107a on the CD8+ T cell surface after activation can be
used to isolate viable antigen-specific CD8+ T cells capable of degranulation (Betts et al.,
2003; Rubio et al., 2003). The only current techniques that enable the isolation of CD8+ T
cells based on their ability to produce cytokines, however, are capture assays (Brosterhus et
al., 1999; Douek et al., 2002b; Lichterfeld et al., 2004). These assays use a bi-specific
antibody that recognizes the cytokine of interest, such as IFNγ, together with lineage
specific markers, such as the pan-lymphocyte receptor CD45. Although useful, this
procedure requires proprietary reagents and alternate procedural steps that can lead to
specificity and sensitivity concerns.
Here, we sought to expand upon this repertoire of sorting methods by developing an assay to
sort functional CD8+ T cells based on TNF production. TNF is an important cytokine
produced by a variety of cell types, including CD8+ T cells, that has pleiotropic effects
including apoptosis induction and complex immunoregulatory and systemic functions (Kull,
1988; Lazdins et al., 1997; Badovinac et al., 2000; Aggarwal, 2003). Compared to other
cytokines, TNF production and release is somewhat unusual, in that TNF is produced
initially as a membrane-bound protein that requires subsequent cleavage by the TNF-α
converting enzyme (TACE) to be released (Bjornberg et al., 1994; Black et al., 1997). Both
forms of TNF are biologically active, with potentially different functions. Thus, membrane-
bound TNF binds preferentially to TNFRII to induce apoptosis, whereas soluble TNF binds
primarily to TNFRI and exerts immunomodulatory properties (Chen and Goeddel, 2002;
Wajant et al., 2003). Importantly, the TNF-α Processing Inhibitor 0 (TAPI-0) can directly
prevent TNF release from the cell surface (Crowe et al., 1995; Pagan et al., 2003; Huse et
al., 2006), effectively trapping TNF on the surface of the producing cell. Through the use of
TAPI-0, we now demonstrate that human antigen-specific CD8+ T cells can be live-sorted
based upon their ability to produce TNF. We show that this assay is highly specific and
compatible with the isolation of mRNA from TNF-producing CD8+ T cells, as well as
culture and in vitro expansion of antigen-specific CD8+ T cells.
2. Materials and Methods
2.1 Cells
Peripheral blood mononuclear cells (PBMC) were obtained from the University of
Pennsylvania’s Center for AIDS Research Human Immunology Core Facility in compliance
with the guidelines set by the respective institutional internal review boards. PBMC were
isolated by standard Hypaque-Ficoll separation and cryopreserved in fetal bovine serum
(FBS; ICS Hyclone, Logan, Utah) containing 10% dimethyl sulfoxide (DMSO; Fisher
Scientific, Pittsburgh, Pennsylvania). Individual peptide stimuli were determined by prior
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epitope mapping using standard IFN-γ ELISpot assays and confirmed by intracellular
cytokine flow cytometry.
2.2 ELISA
Cryopreserved human PBMC were thawed and stimulated with the Epstein-Barr virus
(EBV) EBNA3A-derived RAKFKQLL (RL8) peptide (2 µM) (New England Peptide,
Gardner,MA) restricted by HLA-B*08 (HLA-B8 from hereon unless specified), or
Staphylococcus Enterotoxin B (SEB; 1µg/ml; Sigma-Aldrich, St. Louis, Missouri) for
periods of 4, 2, and 1 hours in the presence or absence of 10 µM TAPI-0 (Calbiochem, La
Jolla, California). Supernatants were then assayed using the TNF Quantikine ELISA Kit
(R&D Systems, Minneapolis, Minnesota).
2.3 Antibodies and peptide/MHC class I tetramers
Monoclonal antibodies (mAbs) for surface staining included: (i) anti-CD4 PECy5-5, anti-
CD19 Alexa-750, anti-CD19 Pac Blue and anti-CD8 TRPE (Invitrogen, Carlsbad,
California); (ii) anti-CD107a FITC, anti-CD3 APC-H7, anti-CD14 Pac Blue, anti-CD16 Pac
Blue, anti-TNF-α PECy7, anti-TNF-α PE and anti-TNF-α APC (BD Biosciences, San Jose,
California); (iii) anti-CD27 PECy5 and anti-CD45RO ECD (Beckman Coulter, Fullerton,
California); and, (iv) anti-CD4 Qdot 585, anti-CD8 Qdot 655, anti-CD57 Qdot 565 and anti-
CD45RO Qdot 705 (custom). For intracellular staining, mAbs included anti-CD3 Qdot 585
(custom) and anti-IFN-γ Alexa-700 (BD Pharmingen, San Diego, California). Custom
conjugations to quantum dot (Qdot) nanocrystals were performed in our laboratory as
described previously (Chattopadhyay et al., 2006) with reagents purchased from Invitrogen.
Peptide/MHC class I tetramers were produced as described previously.(Price et al., 2005)
2.4 TNF surface staining assay
Cryopreserved human PBMC were washed and resuspended at 106 cells/ml in RPMI
(Mediatech Inc., Manassas, Virginia) supplemented with 10% FBS, 1% L-glutamine
(Mediatech Inc.) and 1% penicillin-streptomycin (Lonza, Walkersville, Maryland); complete
RPMI (cRPMI) medium was sterile filtered prior to use. Cells were then stimulated with
SEB (1 µg/ml; Sigma-Aldrich) or peptide (2 µM) as indicated in the presence of 15 µl of
anti-TNF-α PE or anti-TNF-α PECy7 (BD Biosciences) and 10µM of TAPI-0 (Calbiochem)
for 4 hours at 37 °C, 5% CO2. Note that following the 4-hour incubation period with anti-
TNF-α mAb, cells were not re-stained with anti-TNF-α in any subsequent steps. Following
incubation, cells were stained with surface markers and any other relevant markers as
described in section 2.5.
2.5 Flow cytometry staining assay
Cryopreserved PBMC were thawed and rested overnight at 37°C, 5% CO2 in cRPMI
medium at a concentration of 2×106 cells/ml. Subsequently, the cells were washed with
cRPMI and resuspended at a concentration of 1×106 cells/ml with costimulatory mAbs (anti-
CD28 and anti-CD48d; 1 µg/ml final concentration; BD Biosciences). Peptide stimulations
were performed at a final concentration of 2 µM; SEB (1 µg/ml; Sigma-Aldrich) was used
as a positive control. Stimulation tubes were incubated at 37°C, 5% CO2 for 4.5 hours. The
cells were then washed once with PBS and stained with Aqua Blue amine-reactive viability
dye (Invitrogen) for 10 minutes in the dark at room temperature; a mAb cocktail was then
used to stain surface markers for an additional 20 minutes. The cells were then washed again
with PBS containing 1% bovine serum albumin (BSA; Fisher Scientific) and 0.1% sodium
azide (Fisher Scientific) and either fixed in paraformaldehyde (Sigma-Aldrich) or fixed/
permeabilized using the Cytofix/Cytoperm kit (BD Biosciences) according to the
manufacturer's instructions. A cocktail of mAbs against intracellular markers was added to
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the fixed/permeabilized cells, which were then incubated further for 1 hour in the dark at
room temperature. These cells were then washed once with Perm Wash buffer (BD
Biosciences) and fixed in PBS containing 1% paraformaldehyde (Sigma-Aldrich). Fixed
cells were stored in the dark at 4°C until the time of collection.
2.6 Flow cytometric analysis
For each specimen, between 0.5 and 1×106 total events were acquired on a modified LSRII
flow cytometer (BD Immunocytometry Systems, San Jose, California) equipped for the
detection of 18 fluorescent parameters. Anti-mouse Igκ antibody capture beads (BD
Biosciences) were used to prepare individual compensation tubes for each mAb used in the
experiment. Data analysis was performed using FlowJo version 9.1 (TreeStar, Ashland,
Oregon).
2.7 Cell sorting
A 30µM final concentration of TAPI-0 and 100 µl of anti-TNF-α were added to a final cell
concentration of 70×106 PBMC/ml; 15 µg/ml of mouse anti-human CD3 mAb (AbD
Serotech, Oxford, UK) was added to the stimulated condition. Cells were incubated for 4
hours, washed with PBS and stained with Aqua Blue. Subsequently, cells were surface
stained for CD4, CD8, CD14, CD16 and CD19, then sorted using a modified FACSAria
flow cytometer (BD Immunocytometry Systems) at 70 lb/in2. Alternatively, PBMC were
stained with cognate APC-conjugated RL8/HLA-B*0801 tetramer at 37°C for 15 minutes,
washed twice and then surface stained for the markers listed above. Cells from each
experimental condition were either sorted directly into microfuge tubes containing 150 µl
RNAlater (Applied Biosystems, Foster City, California) and stored at −80°C until RNA
extraction or sorted into 1.7 ml Eppendorf tubes for proliferation studies and incubated at
37°C, 5% C02. The sorting scheme is described in Supplemental Figure 1.
2.8 Amnis Image Stream
Cells were stimulated with SEB (1 µg/ml; Sigma-Aldrich) in the presence of TAPI-0
(30µM) and 100µl of anti-TNF-α for 4.5 hours at a final concentration of 70×106 PBMC/ml.
After washing with PBS and staining to exclude non-viable events (Aqua Blue), the cells
were surface stained for CD8 (FITC) and CD14, CD16, CD19 (Pacific Blue). Samples were
run on an ImageStream C28 equipped with three lasers (405nm, 488nm and 658nm). All
samples were collected with 100 mW 405, 200 mW 488, and 80 mW 658 laser powers.
Parameters were set to prevent the collection of small debris and large clumps. From 10,000
to 17,000 events were collected for each experimental sample. Single color controls were
used to create a compensation matrix that was applied to all files to correct for spectral
overlap. The data were analyzed using IDEAs software version 4.0.53(Amnis Corporation,
Seattle, Washington).
2.9 RNA extraction and clonotypic analysis
Total mRNA was extracted using the Oligotex Direct mRNA Mini Kit (Qiagen). Unbiased
amplification of all expressed TRB gene products was conducted using a template-switch
anchored RT-PCR as described previously (Douek et al., 2002a; Price et al., 2004).
Amplicons were purified, cloned and sequenced as described previously(Price et al., 2005).
The international ImMunoGeneTics (IMGT) nomenclature is used throughout.(Lefranc et
al., 1999)
2.10 CFSE staining
Carboxyfluorescein succinimidyl ester (CFSE) staining was performed as described
previously (Brenchley et al., 2002).
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2.11 Figures and data analysis
Canvas software, version 10.4.9 (ACD Systems, Miami, Florida), and Prism software,
version 5.0 (Graphpad, La Jolla, California), were used to create the figures. Labels and
boxes were added to raw data images in Canvas.
3. Results
3.1 Prevention of TNF release from activated PBMC directly ex vivo
TNF is initially produced as a membrane bound protein that is subsequently cleaved by
TACE to release soluble TNF (Black et al., 1997). To prevent this cleavage event, and
thereby trap TNF on the producing cells, we used the TACE protease inhibitor TAPI-0.
Initially, we used TNF ELISA assays to determine the optimal dosage of TAPI-0 necessary
to reduce the cleavage of TNF (Figure 1) and prevent its release from stimulated cells. We
stimulated human PBMC directly ex vivo with SEB in the presence of 0, 2.5, 5, and 10 µM
of TAPI-0 for 4 hours. Unstimulated PBMC incubated with same dosages of TAPI-0 were
included as an additional control (Figure 1). As expected, SEB stimulation potently induced
the production of TNF, which was readily detectable in the culture supernatant. TAPI-0
directly inhibited TNF release from SEB-stimulated human PBMC, reaching a maximal
effect at 10 µM; at this concentration, TNF content in the culture supernatant was reduced
by nearly 4-fold compared to untreated cultures. Together, these data indicate that the TACE
inhibitor TAPI-0 can directly inhibit TNF release from activated human PBMC.
3.2 TNF can be detected by flow cytometry on unfixed/unpermeabilized cells
We next examined whether prevention of TNF release from activated cells by TAPI-0 could
be measured by flow cytometry. As before, we stimulated human PBMC with SEB in the
presence of increasing concentrations of TAPI-0. To maximize the potential staining of
surface-trapped TNF, we included a fluorophore-labeled anti-TNF-α mAb during the
incubation period (Supplemental Figure 2). This technique can enhance the staining of
surface-exposed markers that may be internalized during T cell activation, as has been
shown for other activation-exposed proteins on T cells such as CD107a and CD40L (Betts et
al., 2003; Chattopadhyay et al., 2005). Unlike a standard TNF intracellular cytokine stain, no
secretion inhibitors were included, and the cells were not permeabilized, fixed or re-stained
for TNF following the incubation period. Using this procedure, we could directly visualize
TNF-expressing CD8+ T cells after activation with SEB. Similar to our findings by ELISA,
we found that increasing concentrations of TAPI-0 prevented the release of TNF from
activated CD8+ T cells (a representative flow plot is shown in Figure 2B; n=3). This effect
could be detected both by an increase in the median fluorescence intensity of TNF+CD8+ T
cells (Figure 2A), and by an increase in the total number of TNF+CD8+ T cells (Figure 2B).
Although SEB provides a strong stimulus to CD8+ T cells from nearly any healthy human
donor, we wanted to determine whether TNF production could be detected after an antigen-
specific stimulus. For this purpose, we obtained PBMC from a human donor with a
previously characterized CD8+ T cell response to the HLA-B8-restricted EBNA-3A-derived
EBV epitope RAKFKQLL (EBNA3A-RL8; data not shown). We stimulated donor PBMC
with EBNA3A-RL8 in the presence of increasing TAPI-0 concentrations and anti-TNF-α
mAb. As shown in Figure 2C, TNF was readily detectable on EBNA3A-RL8 specific CD8+
T cells. Similar data were obtained with other donors and different antigenic peptides,
thereby confirming the general applicability of this approach (Supplemental Figure 3 and
data not shown). Furthermore, unlike SEB stimulation, the same dose-response effect was
not observed using peptide stimulation (Figure 2D), suggesting that lower concentrations of
TAPI-0 may be sufficient to trap TNF on the surface of CD8+ T cells after peptide-specific
stimulation.
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Typically, intracellular cytokine staining (ICS) is considered the ‘gold standard’ for the
detection of TNF production by T cells. We therefore compared TNF responses in the CD8+
T cell population as detected by ICS or TNF-surface staining (SS) after stimulation with the
SEB superantigen across 4 different donors. As shown in Figure 3A, the detected SEB-
responding CD8+ T cells that produced TNF in SS conditions varied between 45%–95% of
the traditional ICS methods. Two caveats are important to note from this comparison. First,
background levels of TNF responses tend to be slightly higher using the TNF-SS procedure
compared to TNF-ICS (data not shown). Furthermore, background staining of T cells by
TNF-ICS is often higher than that for other cytokines such as IFNγ and IL-2 (Horton et al.,
2007). Thus, it is not entirely surprising that the TNF background may be detected using the
active labeling procedure for surface staining. Second, TNF expression visualized by SS
does not result in a more uniform MFI for TNF compared to ICS(Figure 3B). This is likely
due to the fact that the label only detects TNF that reaches the cell surface in the SS
procedure, whereas standard ICS conditions trap TNF within the cell, allowing it to
accumulate for staining. Despite these minor caveats, the data indicate that the TNF-SS
procedure achieves a similar efficiency of TNF staining compared to TNF-ICS.
3.3 TNF can be detected on the surface of natural killer cells and CD4+ T cells
Many different lymphocytes are able to produce TNF upon activation, including CD4+ and
CD8+ T cells, NK cells, B cells, monocytes, macrophages and dendritic cells (Wajant et al.,
2003). We therefore examined whether TAPI-0 could similarly allow surface labeling of
some of these other cell types. Similar to our findings with CD8+ T cells, SEB stimulation
of CD4+ T cells induced appreciable amounts of TNF that could be directly surface stained
in the presence of TAPI-0 (Figure 4A–B). Notably, CD4+ T cells often show an appreciable
background level of TNF production in ICS assays (substantially higher than CD8+ T cells);
this was also apparent with the TNF-SS method. Background expression of TNF was not
due to the inclusion of the TAPI-0 inhibitor, as unstimulated CD4+ T cells both with and
without TAPI-0 exhibited similar TNF levels. We also assessed the ability of CD16+ NK
cells to produce TNF upon recognition of K562 target cells. As shown in Figure 4C, TNF
produced by responding NK cells could also be surface labeled in the presence of TAPI-0.
3.4 Direct visualization of TNF on the surface of CD8+ T cells
From the flow-based analysis, it was unclear whether TNF stained on the surface of CD8+ T
cells remained exposed or was subsequently internalized. We therefore used an Amnis
Image Stream cytometer to perform a population-based assessment of TNF-producing CD8+
T cells to determine TNF localization to the cell surface. We stimulated donor PBMC with
SEB in the presence of TAPI-0 and anti-TNF-α conjugated to phycoerythrin for 4 hours.
Approximately 4% of CD8+ cells produced TNF, as shown in Figure 5A (orange box).
Examination of the individual responding TNF+CD8+ T cells revealed a punctate staining
pattern for TNF (Figure 5B, column “TNF-PE”), which often clustered with CD8,
suggesting co-localization (Figure 5B, column "CD8/TNF”). As evidenced by Figure 5A
(red box) and Figure 5C, TNF can also be visualized on non-CD8+ T cells. We next used the
Amnis internalization analysis feature to determine the surface localization of TNF. As
shown in Supplemental Figure 4, 42.6% of the responding TNF+CD8+ cells expressed TNF
on the surface, whereas 57.4% of the cells internalized the fluorophore-labeled TNF.
3.5 TNF+CD8+ T cells are a subset of MHC class I tetramer-defined clonotypes
To definitively show that the TNF-SS assay is antigen-specific, we performed a clonotypic
analysis of ENBA3A-RL8-specific CD8+ T cells from donor 232. CD8+ T cells were
labeled with the RL8/HLA-B*0801 tetramer and, in parallel, stimulated with the EBNA3A-
RL8 peptide in the presence of TAPI-0 and anti-TNF-α mAb. Tetramer+CD8+ or TNF
+CD8+ T cells were then sorted viably using a modified FACS Aria flow cytometer
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(representative data are shown in Figure 6). We then isolated total mRNA and performed a
quantitative, unbiased clonotypic analysis of all expressed TRB gene products. As shown in
Figure 6, the tetramer+CD8+ T cells were composed primarily of two major clonotypes,
TRBV7-2/TRBJ1-5 (CASSLGFGDQPQHF) and TRBV10-3/TRBJ2-3
(CATAGTASTDTQYF), which were equally represented and accounted for ~83% of all
tetramer+CD8+ T cells. These same major clonotypes were also identified after sorting
based on TNF surface expression. Interestingly, the two clonotypes were not equally
represented in the TNF+CD8+ T cell population, indicating that the EBNA3A-RL8-specific
tetramer+CD8+ T cell clonotypes possessed differential TNF production capacities.
3.6 CD8+ T cells identified by TNF-SS can be sorted viably for cell culture and expansion
Thus far, we had established that our TNF-SS assay worked well for flow cytometry, was
reproducible in other cell types, and was applicable for assays requiring isolation of intact
mRNA. We next addressed whether cells sorted on the basis of TNF production could
survive in culture and proliferate. To this end, we stimulated CFSE-stained human PBMC
with anti-CD3 mAb in the presence of TAPI-0 and anti-TNF-α mAb, then sorted CD8+ T
cells using a FACSVantage flow cytometer based on their ability to produce TNF (Figure
7A). Unstimulated CD8+CFSE+ cells were collected as a control. We recovered
approximately 370,000 TNF+CD8+ T cells and placed them into culture for 5 days. The
TNF+CD8+CFSE+ cells underwent 6 rounds of cell division and 34.5% of the cells divided.
An appreciable population did not undergo cell division, which likely represents a lack of
co-stimulation during culture (Figure 7B). Together, these data show that the TNF-SS assay
can be used to isolate viable cells for further culture, as well as for mRNA extraction
directly from functional antigen-specific CD8+ T cells.
4. Discussion
In this study, we have demonstrated a novel procedure by which to isolate activated TNF-
producing lymphocytes. Through the use of a TACE inhibitor, we take advantage of the
unique mechanism of TNF production in order to prevent TNF release from activated T
cells, thereby allowing their direct identification and isolation. We find that this procedure is
highly reproducible, yields similar results to intracellular cytokine staining, and is of
sufficient sensitivity to identify rare populations of antigen-specific CD8+ T cells. We
demonstrate that this assay can be used to isolate viable TNF-producing antigen-specific T
cells, allowing for subsequent studies requiring cell culture or RNA-based analyses.
Many different cell types of both lymphoid and non-lymphoid origin produce TNF; we show
here that our assay is amenable for the identification of TNF-producing CD4+ and CD8+ T
lymphocytes, as well as NK cells. It is important to note in particular that CD4+ T cells
appear to exhibit substantially higher background TNF staining in the absence of stimulation
compared to both CD8+ T cells and NK cells, as has been reported previously (Horton et al.,
2007). Although this would likely reduce the sensitivity of our assay for CD4+ T cell
sorting, combining TNF labeling with another measure of CD4+ T cell activation, such as
upregulation of CD40L (Chattopadhyay et al., 2005) or CD69 (Waldrop et al., 1998) will
reduce sensitivity concerns and still allow CD4+ T cells to be sorted viably and specifically
based on TNF production.
Viable isolation of functional antigen-specific T cells is of particular importance for both
basic and translational immunological research. As we have shown, cell sorting via TACE-
inhibition of TNF release permits the direct isolation of viable antigen-specific CD8+ T cells
for clonotypic analysis of expressed TCRs. Our results demonstrate both the specificity and
utility of the TNF-SS sorting procedure. Thus, compared to CD8+ T cells sorted on the basis
of physical binding to cognate MHC class I tetramer, the TNF-SS sorting procedure
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identified the same dominant clonotypes at the molecular level. Interestingly, however, the
TNF assay revealed that the dominant clonotypes identified by MHC class I tetramer
binding were not equally capable of producing TNF, thereby indicating functional
heterogeneity within the peptide-specific CD8+ T cell population at the clonotypic level.
From the standpoint of translational research, there is a need for procedures that permit the
isolation and expansion of antigen-specific T cells for use in immunotherapeutic strategies.
Commonly, MHC class I tetramers/multimers are used for such isolation procedures;
however, as shown herein and elsewhere (Appay et al., 2000; Oxenius et al., 2002; Gu et al.,
2007; Rehr et al., 2008), not all MHC class I tetramer-binding cells are fully functional. For
instance, not all MHC class I tetramer-binding cells in a population produce IFN-γ after
stimulation with cognate peptide (Goepfert et al., 2000). Alternatively, surface mobilized
CD107a can be used as a means to isolate viable CD8+ T cells. Again, however, not all
antigen-specific CD107a+CD8+ T cells produce IFN-γ(Makedonas et al.; Betts et al., 2004;
Betts et al., 2006). In addition to this, as T cells mature and become terminally
differentiated, TNF production is lost (La Gruta et al., 2004). Together, this demonstrates
functional heterogeneity within the overall population of responding T cells to any given
antigen. Thus, the ability to isolate cells based upon the ability to produce TNF is of
particular use, as it will allow the isolation of CD8+ T cells with increased functional
capacity (Gu et al., 2007) at an earlier stage of differentiation. This may be of great
importance, as T cell-based therapies typically require in vitro expansion of the T cells to
generate sufficient numbers for effective transfer.
In conclusion, we have demonstrated a novel procedure by which to identify and isolate
antigen-specific T cells based upon their ability to produce TNF. This procedure is highly
sensitive and specific, and can be used to isolate viable cells for mRNA-based analyses as
well as subsequent cell culture and proliferation. Alone, or in combination with other
functional sorting methods, this procedure will facilitate further investigations into the
underlying biological properties of antigen-specific T cells. This procedure will also be
valuable for T cell-based immunological therapies, as TNF-producing T cells can either be
enriched or depleted from therapeutic products.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. TAPI-0 prevents TNF secretion
Human PBMC were stimulated directly ex vivo with SEB in the presence of TAPI-0 at the
indicated concentrations. TNF concentration in the supernatant was determined by ELISA.
Open bars depict unstimulated conditions; black bars depict stimulated conditions.
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Figure 2. Expression of TNF on the surface of human PBMC can be quantified by flow
cytometry
(A) Increasing the concentration of TAPI-0 results in an increase in the amount of TNF
trapped on the surface of CD8+ T cells. Open bars depict unstimulated controls; black bars
depict SEB-stimulated conditions (n=3). Whiskers represent standard error. (B&C) Flow
cytometric representation of the dose-dependent increase in TNF surface expression on
SEB-stimulated (B) and EBNA3A-RL8 peptide-stimulated (C) CD8+ T cells. (D) Median
fluorescence intensity (MFI) of surface-stained TNF in EBNA3A-RL8-specific CD8+ T
cells from 3 different human donors with increasing concentrations of TAPI-0. Open bars
depict unstimulated conditions; black bars depict stimulated conditions. Whiskers represent
standard error.
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Figure 3. Cell surface staining for TNF recapitulates intracellular TNF staining
Human PBMC were stimulated with SEB in the presence of TAPI-0 for 4.5 hours and then
either fixed (for surface TNF staining; left panels) or permeabilized (for intracellular TNF
staining; right panels) before analysis. Values represent percent TNF+CD8+ T cells.
Unstimulated control CD8+ T cells are shown in the top panels; SEB-stimulated CD8+ T
cells are shown in the bottom panels.
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Figure 4. Cell surface staining of TNF on activated CD4+ T cells and natural killer cells
(A) TAPI-0 prevents TNF release from activated CD4+ T cells (n=3). Open bars depict MFI
unstimulated controls; black bars depict MFI SEB-stimulated conditions; Whiskers represent
standard error. (B) Flow cytometric representation of the dose-dependent increase in TNF
surface expression on SEB-stimulated CD4+ T cells (C) TNF produced by activated NK
cells can be surface stained after addition of TAPI-0. PBMC from a healthy human donor
were co-cultured at a 1:1 ratio with K562 cells for 4 hours and then stained for the NK cell
marker CD16. The frequency of responding NK cells is shown for unstimulated PBMC (left
panel) and K562-stimulated PBMC (right panel)(D) MFI of CD16+TNF+ cells(n=3); open
bars depict MFI of unstimulated controls; black bars depict MFI of k562 stimulated
conditions
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Figure 5. Direct visualization of TNF staining on the surface of activated CD8+ T cells
Human donor PBMC were stimulated with SEB and stained for TNF production in the
presence of TAPI-0 for 4 hours, then visualized by Image Stream technology. (A)
Representative flow plot of TNF production after SEB stimulation. The orange box
represents TNF+CD8+ events, whereas the red box represents TNF+CD8− events. (B&C)
Representative images of TNF+CD8+ (B) and TNF+CD8− (C) cells display the cellular
localization of TNF.
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Figure 6. Confirmation of TNF-SS assay specificity through TCR clonotypic analysis
(A) Representative flow cytometry plots obtained from resting human PBMC stained with
the RL8/HLA-B*0801 tetramer (upper panel) or stimulated with RL8 peptide for 4.5 hours
in the presence TAPI-0 (50µM) and anti-TNF-α mAb (lower panel). The tetramer+CD8+
and the TNF+CD8+ populations were then sorted for clonotypic analysis (n=2). (B) TRBV
and TRBJ usage, CDR3 amino acid sequence and clonotype frequency are shown for each
distinct sequence. Tetramer+CD8+ T cell clonotypes are shown in the top panel; TNF
+CD8+ T cell clonotypes are shown in the bottom panel. The number (N) of sequences
obtained from the respective sorted populations is shown at the bottom of each panel.
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Figure 7. CD8+ T cells identified by TNF-SS can be sorted viably for cell culture and expansion
(A) Human PBMC were labeled with CFSE, rested overnight and then stimulated (right
panel) with anti-CD3 for 4 hours in the presence of TAPI-0(30µM) and anti-TNF-α mAb.
Control cells were not stimulated (left panel). TNF+CD8+ T cells were then sorted using a
FACS DiVa flow cytometer and placed into culture for 5 days with unstimulated CFSE-
autologous PBMC. (B) CFSE proliferation plots of TNF−CD8+CFSE+ (unstimulated
control, left plot) and TNF+CD8+CFSE+ (anti-CD3 stimulated, right plot) T cells. The
CFSE− cells in each plot are unstimulated autologous feeder cells remaining in the culture
after the incubation period.
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